Search

Your search keyword '"Mirabile, Aurora"' showing total 142 results
Start Over Author "Mirabile, Aurora"
142 results on '"Mirabile, Aurora"'

2. WCN24-1677 METASTATIC HEAD AND NECK CANCER AND HIGH CALORIE AND PROTEIN DIET: WHEN THE END JUSTIFIES THE MEANS IN THE ONCONEPHROLOGICAL UNIVERSE

Author

Trevisani, Francesco, primary, Cardellini, Sara, additional, Paccagnella, Matteo, additional, Floris, Matteo, additional, Bettiga, Arianna, additional, Ghidini, Michele, additional, Simeoni, Mariadelina, additional, Garrone, Ornella, additional, Dell'Oca, Italo, additional, Giordano, Leone, additional, Mele, Roberto, additional, Mirabile, Aurora, additional, and Laurenti, Fabiana, additional

Published
2024
Full Text
View/download PDF

4. From Tumor Macroenvironment to Tumor Microenvironment: The Prognostic Role of the Immune System in Oral and Lung Squamous Cell Carcinoma.

Author

Battista, Rosa Alessia, Pini, Giacomo Maria, Finco, Alex, Corso, Filippo, Galli, Andrea, Arrigoni, Gianluigi, Doglioni, Claudio, Callea, Marcella, Paccagnella, Matteo, Porcu, Luca, Filipello, Federica, Mazzola, Marco, Foggetti, Giorgia, Gregorc, Vanesa, Giordano, Leone, Bussi, Mario, Mirabile, Aurora, and Veronesi, Giulia

Subjects
ANTIGEN analysis, SQUAMOUS cell carcinoma, NEUTROPHIL lymphocyte ratio, REFERENCE values, INFLAMMATORY mediators, RESEARCH funding, IMMUNE system, LYMPHOCYTES, RETROSPECTIVE studies, TREATMENT effectiveness, PLATELET lymphocyte ratio, ANTIGENS, MONOCYTE lymphocyte ratio, LUNG tumors, TUMOR classification, PROGRESSION-free survival, COMORBIDITY, OVERALL survival, EVALUATION
Abstract

Simple Summary: This study explores the involvement of the immune system in oral and lung squamous cell carcinoma. Given the increasing recognition of the immune system's significance in cancer, the study analyzes key components of both tumor macroenvironment and microenvironment. In detail, the focus is on systemic inflammation markers, such as Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR). Additionally, this study investigates Tumor-Infiltrating Lymphocytes (TILs) and CD8+ cells in the tumor microenvironment. We aimed to better understand the impact of these prognostic factors on overall survival (OS) and disease-free survival (DSF) in order to enhance cancer risk stratification and guide therapeutic decisions. Background: The interplay between cancer cells and the immune system is crucial in cancer progression and treatment. In this regard, the tumor immune microenvironment and macroenvironment, marked by systemic inflammation markers and TILs, could be considered key prognostic factors in tumors, including oral and lung squamous cell carcinoma. Methods: We conducted a retrospective clinical study on patients with Oral Squamous Cell Carcinoma (OSCC) and Lung Squamous Cell Carcinoma (LUSCC), examining stages, comorbidities, treatments, and outcomes. We evaluated the prognostic significance of pre-surgical systemic inflammation markers and tumor microenvironment composition. Results: Associations were found between systemic inflammation markers—NLR, MLR, and PLR—and tumor microenvironment factors, such as TILs and CD8+ cell prevalence—elevated inflammation markers correlated with advanced stages. Specifically, NLR was prognostic in OSCC, whereas PLR was prognostic in LUSCC. Using a cutoff value, we divided our tumor samples into two prognostic groups. Moreover, TILs levels >15% of tumor stroma correlated with prolonged overall survival in both OSCC and LUSCC, while increased CD8+ expression was linked to extended disease-free survival in LUSCC. Discussion: Systemic inflammation markers and TILs can be valuable prognostic factors of survival, highlighting the immune response's role in OSCC and LUSCC. Despite limited clinical integration of the presented cohorts due to a lack of standardization, we concluded that analyzing tumor immune profiles may offer novel prognostic insights. Conclusions: Future integration into cancer classification could improve risk stratification and treatment guidance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Cats

Author

Dall’Ara, Paola, primary, Lauzi, Stefania, additional, Turin, Lauretta, additional, Servida, Francesco, additional, Barbieri, Laura, additional, Zambarbieri, Jari, additional, Mazzotti, Giulia, additional, Granatiero, Federico, additional, Scarparo, Elena, additional, Mirabile, Aurora, additional, Bo, Stefano, additional, and Filipe, Joel, additional

Published
2023
Full Text
View/download PDF

9. Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience

Author

Deantoni, Chiara L., Mirabile, Aurora, Chiara, Anna, Giannini, Laura, Midulla, Martina, Del Vecchio, Antonella, Fiorino, Claudio, Fodor, Andrei, Di Muzio, Nadia G., and Dell’Oca, Italo

Abstract

Aims: Low skeletal muscle mass index (SMI) has recently emerged as an independent prognostic factor in oncological patients and it is linked with poor survival and higher treatment toxicity. The present study aims to determine the possible impact of low SMI on survival and acute toxicity in oropharyngeal patients.Methods: Seventy-six patients with locally advanced oropharyngeal squamous cell carcinoma (stage III-IVC) were treated in our institution with Helical TomoTherapy® (HT - Accuray, Maddison, WI, USA) between 2005 and 2021. All patients received concomitant platinum-based chemotherapy (CT) (at least 200 mg/m2). The SMI was determined using the calculation of cross-sectional area at C3. Twenty patients (26%) presented pre-treatment low SMI, according to Chargi definitions.Results: All patients concluded the treatment. Thirteen patients with low SMI (65%) and 22 patients with normal SMI (39%) presented acute toxicity greater than or equal to grade 3, but this difference was not statistically significant (p-value = 0.25). Overall survival was analyzed in 65 patients, excluding those who finished CT-RT less than six months before the analysis. Overall survival was significantly lower in low SMI versus normal SMI patients (p-value = 0.035). Same difference was observed in N0-N2a patients, suggesting an important role of SMI also in lower nodal burden and putatively better prognosis.Conclusions: Although the results are limited to a small population, our case series has the advantage to be very homogeneous in patients and treatment characteristics. In our setting, SMI demonstrated a crucial impact on overall survival. Further investigation with larger samples is necessary to confirm our results to improve patient outcomes.

Published
2024
Full Text
View/download PDF

10. Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)

Author

Roila, Fausto, Fumi, Guglielmo, Ruggeri, Benedetta, Antonuzzo, Andrea, Ripamonti, Carla, Fatigoni, Sonia, Cavanna, Luigi, Gori, Stefania, Fabi, Alessandra, Marzano, Nicola, Graiff, Claudio, De Sanctis, Vitaliana, Mirabile, Aurora, Serpentini, Samantha, Bocci, Chiara, Pino, Maria Simona, Cilenti, Giuseppina, Verusio, Claudio, Ballatori, Enzo, and on behalf of NICSO (Network Italiano per le Cure di Supporto in Oncologia)

Published
2019
Full Text
View/download PDF

12. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Author

David Carbone, Michael Sharpnack, Kai He, Lisa H. Butterfield, Alexander M. M. Eggermont, Maria Gonzalez-Cao, Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowskyj, Ana Giménez-Capitán, Cristina Teixidó, Miguel Angel Molina-Vila, Santiago Viteri Ramírez, Salvador Martin Algarra, Elisabeth Pérez-Ruiz, Iván Márquez-Rodas, Delvys Rodriguez-Abreu, Remei Blanco, Teresa Puértolas, Maria Angeles Royo, Rafael Rosell, Maria Libera Ascierto, Svetlana Hamm, Tanja Wulff, Kerstin Kronthaler, Sabine Schrepfer, Ulrike Parnitzke, Anne Catherine Bretz, Roland Baumgartner, Veronica Ferrucci, Francesco Paolo Pennino, Luisa Dassi, Fatemeh Asadzadeh, Roberto Siciliano, Marianeve Carotenuto, Daniela Spano, Cristina Maria Chiarolla, Adelaide Greco, Monica Cantile, Maurizio Di Bonito, Gerardo Botti, Vandenbussche Jonathan, Gevaert Kris, Massimo Zollo, Teresa Amaral, Ioanna Tampouri, Ulrike Keim, Thomas Eigentler, Claus Garbe, Andrea Forschner, Alessandra Cesano, Sarah Warren, Duane Moogk, Kaitao Li, Zhou Yuan, Shi Zhong, Zhiya Yu, Ivan Liadi, William Rittase, Victoria Fang, Janna Dougherty, Arianne Perez-Garcia, Iman Osman, Navin Varadarajan, Nicholas P. Restifo, Alan Frey, Cheng Zhu, Michelle Krogsgaard, Claire Vanpouille-Box, Silvia C. Formenti, Sandra Demaria, Cristiana Lo Nigro, Alexander Renziehausen, Andreas G. Tzakos, Hexiao Wang, Bhavya Rao, Rubeta Matin, Catherine Harwood, Daniela Vivenza, Federica Tonissi, Marcella Occelli, Lynda Weir, Su Li, Van Ren Sim, Kevin O’Neill, Alan Evans, Alastair Thompson, Peter Szlosarek, Colin Fleming, Charlotte Proby, Nelofer Syed, Marco Merlano, Tim Crook, Robert Ferguson, Danny Simpson, Carlos Martinez, Matjaz Vogelsang, Esther Kazlow, Melissa Wilson, Anna Pavlick, Jeffrey Weber, Ryan Sullivan, Keith Flaherty, Antoni Ribas, Tomas Kirchhoff, Antonio D’Avino, Licia Guida, Augusto Cosacco, Roberta D’Aniello, Piera Maiolino, Teresa Tramontano, Maria R. Sarno, Ida Palazzo, Angela Di Napoli, Gianclaudio Acunzo, Mariarosanna De Fina, Antonia Silvestri, Monica Specchia, Michela Musacchio, Gianfranco Giglio, Francesco Carrozza, Liberato Di Lullo, Gian Marco De Maddi, Adele Venturelli, Elisabetta Gambale, Alessia Gatta, Davide Brocco, Consiglia Carella, Michele De Tursi, Thomas F. Gajewski, Costanza M. Cristiani, Rossana Tallerico, Valeria Ventura, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Eliska Selinger, Cinzia Garofalo, Elina Staaf, Ester Simeone, Antonio M. Grimaldi, Genny del Zotto, Elio Gulletta, Gennaro Ciliberto, Alessandro Moretta, Paolo A. Ascierto, Ennio Carbone, Susan Costantini, Angela Sorice, Francesca Capone, Alfredo Budillon, Carolina Cauchi, Grazia Sciancalepore, Michela Rovera, Chiara Varamo, Zelda Seia, Stefania Palazzini, Fabiana Errico, Davide Basso, Laura Quaranta, Giuseppe Forte, Fulvio Lavagna, Silvia Violante, Paolo Bosio, Laura Lattanzio, Marco C Merlano, Mike Gowen, Jeremy Tchack, Hua Zhou, Keith Giles, Scott Paschke, Una Moran, David Fenyo, Aris Tsirigos, Michael Pacold, Silvana Morello, Claudia Sorrentino, Diana Giannarelli, Aldo Pinto, Federica Fratangelo, Rosaria Falcone, Vito Vanella, Dirk Schadendorf, Karl Lewis, Michele Maio, Lev Demidov, Mario Mandalà, Igor Bondarenko, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant Goodman, Brian Simmons, Chenglin Ye, Gregory Hooper, Matthew J. Wongchenko, Yibing Yan, Frank Hermann, Astrid Ammendola, René Bartz, Bulotta Alessandra, Colombo Letizia, Mirabile Aurora, Lazzari Chiara, Mercuri Santo Raffaele, Parolini Danilo, Rizzo Nathalie, Martella Stefano, Modorati Giulio, Brianti Pina, Cestone Enza, Bellinzona Federica, Miserocchi Elisabetta, Gianni Luca, Gregorc Vanesa, Sanjiv Agarwala, B. Mark Smithers, Axel Haushild, Eric Watcher, Luigi Fattore, Ciro Francesco Ruggiero, Domenico Liguoro, Andrea Cerri, Maria Elena Pisanu, and Rita Mancini

Subjects
Medicine
Published
2018
Full Text
View/download PDF

14. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers:The protocol for the rare head and neck cancers

Author

Trama, Annalisa, Licitra, Lisa, Cavalieri, Stefano, Bonfarnuzzo, Simone, Baili, Paolo, Ciarfella, Antonio, Parente, Pablo, Almadori, Giovanni, Ansarin, Mohssen, Bacigalupo, Almalina, Baumeister, Philipp, Baujat, Bertrand, Bossi, Paolo, Cavalera, Elisa, Cercato, Maria Cecilia, Dieleman, Francois, Fakhry, Nicolas, Ferraresi, Virginia, Gaino, Francesca, Galizia, Danilo, Halamkova, Jana, Halme, Elina, Hardillo, Jose, Hofauer, Benedikt, Kinloch, Emma, Livi, Lorenzo, Locati, Laura Deborah, Mattheis, Stefan, Mercante, Giuseppe, Mirabile, Aurora, Molteni, Gabriele, Orlandi, Ester, Persio, Roberto, Sciallero, Stefania, Smeele, Ludi, Tagliabue, Marta, Valentini, Valentino, Van Harpen, Carla, Westphalen, Christoph Benedikt, Botta, Laura, Trama, Annalisa, Licitra, Lisa, Cavalieri, Stefano, Bonfarnuzzo, Simone, Baili, Paolo, Ciarfella, Antonio, Parente, Pablo, Almadori, Giovanni, Ansarin, Mohssen, Bacigalupo, Almalina, Baumeister, Philipp, Baujat, Bertrand, Bossi, Paolo, Cavalera, Elisa, Cercato, Maria Cecilia, Dieleman, Francois, Fakhry, Nicolas, Ferraresi, Virginia, Gaino, Francesca, Galizia, Danilo, Halamkova, Jana, Halme, Elina, Hardillo, Jose, Hofauer, Benedikt, Kinloch, Emma, Livi, Lorenzo, Locati, Laura Deborah, Mattheis, Stefan, Mercante, Giuseppe, Mirabile, Aurora, Molteni, Gabriele, Orlandi, Ester, Persio, Roberto, Sciallero, Stefania, Smeele, Ludi, Tagliabue, Marta, Valentini, Valentino, Van Harpen, Carla, Westphalen, Christoph Benedikt, and Botta, Laura

Abstract

Care for head and neck cancers is complex in particular for the rare ones. Knowledge is limited and histological heterogeneity adds complexity to the rarity. There is a wide consensus that to support clinical research on rare cancer, clinical registries should be developed within networks specializing in rare cancers. In the EU, a unique opportunity is provided by the European Reference Networks (ERN). The ERN EURACAN is dedicated to rare adults solid cancers, here we present the protocol of the EURACAN registry on rare head and neck cancers (ClinicalTrials.gov Identifier: NCT05483374). Study design Registry-based cohort study including only people with rare head and neck cancers. Objectives 1.To help describe the natural history of rare head and neck cancers; 2.To evaluate factors that influence prognosis; 3.To assess treatment effectiveness; 4.To measure indicators of quality of care. Methods Settings and participants It is an hospital based registry established in hospitals with expertise in head and neck cancers. Only adult patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear will be included in the registry. This registry won t select a sample of patients. Each patient in the facility who meets the above mentioned inclusion criteria will be followed prospectively and longitudinally with follow-up at cancer progression and / or cancer relapse or patient death. It is a secondary use of data which will be collected from the clinical records. The data collected for the registry will not entail further examinations or admissions to the facility and/or additional appointments to those normally provided for the patient follow-up. Variables Data will be collected on patient characteristics (eg. patient demographics, lifestyle, medical history, health status); exposure data (eg. disease, procedures, treatments of interest) and outcomes (e.g. survival, progression

Published
2023

15. Prevalence of Serum Antibody Titers against Core Vaccine Antigens in Italian Cats.

Author

Dall'Ara, Paola, Lauzi, Stefania, Turin, Lauretta, Servida, Francesco, Barbieri, Laura, Zambarbieri, Jari, Mazzotti, Giulia, Granatiero, Federico, Scarparo, Elena, Mirabile, Aurora, Bo, Stefano, and Filipe, Joel

Subjects
IMMUNOGLOBULINS, ANTIBODY titer, SERUM, FELINE panleukopenia virus, CATS, ANTIGENS, RESPIRATORY diseases
Abstract

Feline core vaccines strongly recommended for all cats are against Feline panleukopenia virus (FPV), Felid herpesvirus type 1 (FeHV-1), and Feline calicivirus (FCV), but cats can be classified as low- and high-risk based on their lifestyle. The aim of this study was to determine the actual seroprotection against FPV, FeHV-1, and FCV in a large cohort of Italian cats by using the VacciCheck test. A total of 740 cats (567 owned and 173 stray cats; 435 vaccinated and 305 unvaccinated) were analyzed for Protective Antibody Titers (PATs). Differences related to origin, sex, age, breed, FIV/FeLV status, health status, and time elapsed since last vaccination were evaluated. Less than half of the entire cohort (36.4%) had PATs for all three diseases simultaneously, increasing to 48.6% if weak positive values were also considered and 50.3% when considering only the 435 vaccinated cats. Particularly, antibodies were detected against FCV, FPV, and FeHV-1 at protective titers (PATs) in 78.6%, 68.1, and 49.1% of the cats, respectively. In general, owned, neutered, and adult FIV- and/or FeLV-negative cats were the most protected categories, even if not always for the three viruses. Most cats maintained high PATs for 3 years or longer after vaccination against FPV and FCV but not FeHV-1. Long-lasting protective immunity persisted for many years after the last vaccination (more than 18 years in the oldest cats). Nevertheless, since not all cats were protected after so many years and for all pathogens, checking protection via antibody titration could be the best choice to prevent immunity breakdowns. The discussion also focuses on the reliability of antibody titration for the two URTD (upper respiratory tract disease) viruses which, unlike for FPV, is not widely accepted as a valid index of protection. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers

Author

Trama, Annalisa, primary, Licitra, Lisa, additional, Cavalieri, Stefano, additional, Bonfarnuzzo, Simone, additional, Baili, Paolo, additional, Ciarfella, Antonio, additional, Parente, Pablo, additional, Almadori, Giovanni, additional, Ansarin, Mohssen, additional, Bacigalupo, Almalina, additional, Baumeister, Philipp, additional, Baujat, Bertrand, additional, Bossi, Paolo, additional, Cavalera, Elisa, additional, Cercato, Maria Cecilia, additional, Dieleman, Francois, additional, Fakhry, Nicolas, additional, Ferraresi, Virginia, additional, Gaino, Francesca, additional, Galizia, Danilo, additional, Halamkova, Jana, additional, Halme, Elina, additional, Hardillo, Jose, additional, Hofauer, Benedikt, additional, Kinloch, Emma, additional, Livi, Lorenzo, additional, Locati, Laura Deborah, additional, Mattheis, Stefan, additional, Mercante, Giuseppe, additional, Mirabile, Aurora, additional, Molteni, Gabriele, additional, Orlandi, Ester, additional, Persio, Roberto, additional, Sciallero, Stefania, additional, Smeele, Ludi, additional, Tagliabue, Marta, additional, Valentini, Valentino, additional, Van Harpen, Carla, additional, Westphalen, Christoph Benedikt, additional, and Botta, Laura, additional

Published
2023
Full Text
View/download PDF

18. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus

Author

Mirabile, Aurora, Numico, Gianmauro, Russi, Elvio G., Bossi, Paolo, Crippa, Fulvio, Bacigalupo, Almalina, De Sanctis, Vitaliana, Musso, Stefania, Merlotti, Anna, Ghi, Maria Grazia, Merlano, Marco C., Licitra, Lisa, Moretto, Francesco, Denaro, Nerina, Caspiani, Orietta, Buglione, Michela, Pergolizzi, Stefano, Cascio, Antonio, Bernier, Jacques, Raber-Durlacher, Judith, Vermorken, Jan B., Murphy, Barbara, Ranieri, Marco V., and Dellinger, R. Phillip

Published
2015
Full Text
View/download PDF

21. Skeletal Muscle Depletion and Major Postoperative Complications in Locally-Advanced Head and Neck Cancer: A Comparison between Ultrasound of Rectus Femoris Muscle and Neck Cross-Sectional Imaging

Author

Galli, Andrea, primary, Colombo, Michele, additional, Prizio, Carmine, additional, Carrara, Giulia, additional, Lira Luce, Francesca, additional, Paesano, Pier Luigi, additional, Della Vecchia, Giovanna, additional, Giordano, Leone, additional, Bondi, Stefano, additional, Tulli, Michele, additional, Di Santo, Davide, additional, Mirabile, Aurora, additional, De Cobelli, Francesco, additional, and Bussi, Mario, additional

Published
2022
Full Text
View/download PDF

25. P-62 Helical Intensity Modulated Radiotherapy 18 FDG PET guided in locally advanced oropharyngeal cancer: a mono-institutional experience

Author

Deantoni, Chiara Lucrezia, primary, Chiara, Anna, additional, Mirabile, Aurora, additional, Giordano, Leone, additional, Bondi, Stefano, additional, Broggi, Sara, additional, Baroni, Simone, additional, Fodor, Andrei, additional, Zerbetto, Flavia, additional, Tummineri, Roberta, additional, Gregorc, Vanesa, additional, Picchio, Maria, additional, Fiorino, Claudio, additional, Oca, Italo Dell, additional, and Muzio, Nadia Gisella Di, additional

Published
2021
Full Text
View/download PDF

27. A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study

Author

Corino, Valentina D. A., primary, Bologna, Marco, additional, Calareso, Giuseppina, additional, Licitra, Lisa, additional, Ghi, Mariagrazia, additional, Rinaldi, Gaetana, additional, Caponigro, Francesco, additional, Morelli, Franco, additional, Airoldi, Mario, additional, Allegrini, Giacomo, additional, Cassano, Alessandra, additional, Ferrari, Daris, additional, Mirabile, Aurora, additional, Tosoni, Alicia, additional, Galizia, Danilo, additional, Merlano, Marco, additional, Sponghini, Andrea, additional, Moretti, Gabriella, additional, Mainardi, Luca, additional, and Bossi, Paolo, additional

Published
2021
Full Text
View/download PDF

28. Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients

Author

Alfieri, Salvatore, primary, Romanò, Rebecca, additional, Bologna, Marco, additional, Calareso, Giuseppina, additional, Corino, Valentina, additional, Mirabile, Aurora, additional, Ferri, Andrea, additional, Bellanti, Luca, additional, Poli, Tito, additional, Marcantoni, Alessandra, additional, Grosso, Enrica, additional, Tarsitano, Achille, additional, Battaglia, Salvatore, additional, Blengio, Fulvia, additional, De Martino, Iolanda, additional, Valerini, Sara, additional, Vecchio, Stefania, additional, Richetti, Antonella, additional, Deantonio, Letizia, additional, Martucci, Francesco, additional, Grammatica, Alberto, additional, Ravanelli, Marco, additional, Ibrahim, Toni, additional, Caruso, Damiano, additional, Locati, Laura Deborah, additional, Orlandi, Ester, additional, Bossi, Paolo, additional, Mainardi, Luca, additional, and Licitra, Lisa F., additional

Published
2021
Full Text
View/download PDF

29. Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer

Author

Gregorc, Vanesa, primary, Lazzari, Chiara, additional, Mandalá, Mario, additional, Ippati, Stefania, additional, Bulotta, Alessandra, additional, Cangi, Maria Giulia, additional, Khater, Abdelrahman, additional, Viganò, Maria Grazia, additional, Mirabile, Aurora, additional, Pecciarini, Lorenza, additional, Ogliari, Francesca Rita, additional, Arrigoni, Gianluigi, additional, Grassini, Greta, additional, Veronesi, Giulia, additional, and Doglioni, Claudio, additional

Published
2021
Full Text
View/download PDF

30. History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature

Author

Lazzari, Chiara, primary, Mirabile, Aurora, additional, Bulotta, Alessandra, additional, Viganó, Maria Grazia, additional, Ogliari, Francesca Rita, additional, Ippati, Stefania, additional, DellOca, Italo, additional, Santarpia, Mariacarmela, additional, Lorusso, Vincenza, additional, Reck, Martin, additional, and Gregorc, Vanesa, additional

Published
2021
Full Text
View/download PDF

31. Uncommon Site of Metastasis and Prolonged Survival in Patients with Anaplastic Thyroid Carcinoma: A Systematic Review of the Literature

Author

Mirabile, Aurora, primary, Biafora, Matteo, additional, Giordano, Leone, additional, Arrigoni, Gianluigi, additional, Cangi, Maria Giulia, additional, Dell’Oca, Italo, additional, Lira Luce, Francesca, additional, Di Santo, Davide, additional, Galli, Andrea, additional, Tulli, Michele, additional, Mellone, Renata, additional, Valsecchi, Davide, additional, Gregorc, Vanesa, additional, and Bussi, Mario, additional

Published
2020
Full Text
View/download PDF

32. Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell carcinoma of the head and neck (SCCHN).

Author

Alfieri, Salvatore, primary, Romanò, Rebecca, additional, Bologna, Marco, additional, Calareso, Giuseppina, additional, Mirabile, Aurora, additional, Ferri, Andrea, additional, Marcantoni, Alessandra, additional, Grosso, Enrica, additional, Tarsitano, Achille, additional, Valerini, Sara, additional, Vecchio, Stefania, additional, Deantonio, Letizia, additional, Blengio, Fulvia, additional, Ibrahim, Toni, additional, Mancinelli, Moela, additional, Ascoli, Francesco, additional, Bossi, Paolo, additional, Locati, Laura Deborah, additional, Mainardi, Luca, additional, and Licitra, Lisa F., additional

Published
2020
Full Text
View/download PDF

35. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Author

Signorelli, Diego, Giannatempo, Patrizia, Grazia, Giulia, Aiello, Marco Maria, Bertolini, Federica, Mirabile, Aurora, Buti, Sebastiano, Vasile, Enrico, Scotti, Vieri, Pisapia, Pasquale, Cona, Maria Silvia, Rolfo, Christian, and Malapelle, Umberto

Subjects
Article Subject
Abstract

Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection.

Published
2019
Full Text
View/download PDF

38. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer

Author

Alfieri, Salvatore, Ripamonti, Carla I, Marceglia, SARA RENATA FRANCESCA, Orlandi, Ester, Iacovelli, Nicola A, Granata, Roberta, Cavallo, Anna, Pozzi, Paolo, Boffi, Roberto, Bergamini, Cristiana, Imbimbo, Martina, Pala, Laura, Resteghini, Carlo, Mirabile, Aurora, Locati, Laura D, Licitra, Lisa, Bossi, Paolo, Alfieri, Salvatore, Ripamonti, Carla I, Marceglia, SARA RENATA FRANCESCA, Orlandi, Ester, Iacovelli, Nicola A, Granata, Roberta, Cavallo, Anna, Pozzi, Paolo, Boffi, Roberto, Bergamini, Cristiana, Imbimbo, Martina, Pala, Laura, Resteghini, Carlo, Mirabile, Aurora, Locati, Laura D, Licitra, Lisa, and Bossi, Paolo

Subjects
Adult, Male, Mucositis, Analgesics, oropharyngeal cancer, Smoking, opioids, Chemoradiotherapy, Middle Aged, smoking, Analgesics, Opioid, Oropharyngeal Neoplasms, opioid, Humans, oral mucositis, pain, Female, oral mucositi, Aged
Abstract

Oral mucositis (OM)-related pain affects most patients with head and neck cancer during treatments, but its management is not standardized.We retrospectively collected data about the opioid therapy used for OM-induced pain in all patients with oropharyngeal cancer treated with chemoradiotherapy (CRT) between 2009 and 2013. To compare the different opioids, a conversion into oral morphine equivalent daily dose (OMEDD) was performed. The highest OMEDD (h-OMEDD) and the opioids' weekly increase were associated with patient, tumor, or treatment-related characteristics in order to identify predictive factors of opioid consumption.Ninety-seven percent of patients received opioids. The h-OMEDD was significantly correlated with a higher OM-grade and a lower smoking history. The weekly opioids' increase was higher in patients with lower smoking history and human papillomavirus (HPV) positivity.Opioid therapy remains the mainstay for OM-related pain management during CRT. The role of previous smoking and HPV on opioid use needs further confirmations. © 2016 Wiley Periodicals, Inc. Head Neck 38: E1521-E1527, 2016.

Published
2015

39. Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer

Author

Orlandi, Ester, primary, Miceli, Rosalba, additional, Infante, Gabriele, additional, Mirabile, Aurora, additional, Alterio, Daniela, additional, Cossu Rocca, Maria, additional, Denaro, Nerina, additional, Vigna-Taglianti, Riccardo, additional, Merlotti, Annamaria, additional, Schindler, Antonio, additional, Pizzorni, Nicole, additional, Fallai, Carlo, additional, Licitra, Lisa, additional, and Bossi, Paolo, additional

Published
2018
Full Text
View/download PDF

42. Role of nutrition in incidence and management of cancer therapy-induced diarrhea (CTID): HEAT (Health Eat and Toxicity) prospective interventional study and preliminary data.

Author

Mirabile, Aurora, primary, Vecchio, Erika, additional, Falvella, Stefania, additional, Barbarini, Lucia, additional, Butti, Chiara, additional, Ciambelli, Fabrizio, additional, Bovio, Antonella, additional, Pauli, Sergio, additional, Ricci, Isabella, additional, Frigo, Fiorenza, additional, Del Grosso, Elisabetta, additional, Aloisio, Enrica, additional, Oliva, Giovanna, additional, and Artale, Salvatore Agatino, additional

Published
2017
Full Text
View/download PDF

43. Oncological supportive-care unit (OSU): An effective toxicity management model.

Author

Mirabile, Aurora, primary, Foglia, Emanuela, additional, Frigo, Fiorenza, additional, Del Grosso, Elisabetta, additional, Barbarini, Lucia, additional, Bovio, Antonella, additional, Butti, Chiara, additional, Ciambelli, Fabrizio, additional, Pauli, Sergio, additional, Ricci, Isabella, additional, Gargiola, Elisabetta, additional, Aloisio, Enrica, additional, Oliva, Giovanna, additional, and Artale, Salvatore Agatino, additional

Published
2017
Full Text
View/download PDF

44. Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy

Author

Mirabile, Aurora, primary, Vismara, Chiara, additional, Crippa, Fulvio, additional, Bossi, Paolo, additional, Locati, Laura, additional, Bergamini, Cristiana, additional, Granata, Roberta, additional, Resteghini, Carlo, additional, Conte, Eutilia, additional, Morelli, Daniele, additional, Scarpellini, Paolo, additional, and Licitra, Lisa, additional

Published
2015
Full Text
View/download PDF

46. Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.

Author

Bossi, Paolo, primary, De Cecco, Loris, additional, Perrone, Federica, additional, Cortelazzi, Barbara, additional, Cossu Rocca, Maria, additional, Marco, Siano, additional, Sponghini, Andrea, additional, Bergamini, Cristiana, additional, Locati, Laura D., additional, Mirabile, Aurora, additional, Granata, Roberta, additional, Resteghini, Carlo, additional, Pilotti, Silvana, additional, Canevari, Silvana, additional, and Licitra, Lisa F., additional

Published
2013
Full Text
View/download PDF

48. Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).

Author

Locati, Laura D., primary, Bossi, Paolo, additional, Civelli, Enrico M., additional, Perrone, Federica, additional, Bergamini, Cristiana, additional, Cortelazzi, Barbara, additional, Quattrone, Pasquale, additional, Imbimbo, Martina, additional, Mirabile, Aurora, additional, Granata, Roberta, additional, Resteghini, Carlo, additional, Mariani, Luigi, additional, Tosarello, Davide, additional, Cassani, Camilla, additional, Marchiano', Alfonso, additional, Saibene, Gabriella, additional, Pilotti, Silvana, additional, and Licitra, Lisa F., additional

Published
2013
Full Text
View/download PDF

49. Association between salivary cytokine levels and chemoradiotherapy-induced toxicities in head and neck cancer patients.

Author

Bossi, Paolo, primary, Filipazzi, Paola, additional, Resteghini, Carlo, additional, Miceli, Rosalba, additional, Orlandi, Ester, additional, Locati, Laura, additional, Fallai, Carlo, additional, Tana, Silvia, additional, Cova, Agata, additional, Squarcina, Paola, additional, Rodolfo, Monica, additional, Bergamini, Cristiana, additional, Granata, Roberta, additional, Mirabile, Aurora, additional, Rivoltini, Licia, additional, and Licitra, Lisa F., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results